Veronica Pezzella
Hôpital Cardiologique du Haut-Lévêque(FR)UniCancer Group(FR)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial(2024)154 cited
- → Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.(2023)105 cited
- → Very Late Heart Transplant Rejection Is Associated with Microvascular Injury, Complement Deposition and Progression to Cardiac Allograft Vasculopathy(2011)95 cited
- → Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer(2021)24 cited
- → Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol(2020)18 cited
- → An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.(2017)17 cited
- → Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study(2014)16 cited
- → An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.(2018)5 cited
- → LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study(2023)3 cited
- → UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis(2018)3 cited